KCL-286 is an orally bioavailable, blood-brain barrier-permeable retinoic acid receptor (RAR) β2 agonist (EC50 = 1.9 nM) with selectivity over RARα (EC50 = 26 nM) and RARγ (EC50 = 11 nM). It activates RARβ2 in injured neurons, promotes axonal regeneration of spinal and sensory nerves by overcoming the inhibitory environment of the central nervous system, modulates neuroinflammation and extracellular matrix molecules, and regulates chondroitin sulfate proteoglycan (CSPG) expression via neuronal secretion of decorin to facilitate myelination and support axonal growth. KCL-286 is used in research on spinal cord injury and traumatic nerve injury.